{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T09:17:14Z","timestamp":1788599834883,"version":"build-2803163510"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.jns.2020.116903","type":"journal-article","created":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T14:07:01Z","timestamp":1589551621000},"page":"116903","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["The efficacy of perampanel as adjunctive therapy in drug-resistant focal epilepsy in a \u201creal world\u201d context: focus on temporal lobe epilepsy"],"prefix":"10.1016","volume":"415","author":[{"given":"Angelo","family":"Pascarella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi Francesco","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Di Gennaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"D'Aniello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Ferlazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazareno","family":"Gagliostro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ursini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Bonanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Paciello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Romigi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Aguglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovambattista","family":"De Sarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gambardella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Labate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2020.116903_bb0005","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/17460441.2019.1566318","article-title":"The impact of perampanel and targeting AMPA transmission on anti-seizure drug discovery","volume":"14","author":"Lattanzi","year":"2019","journal-title":"Expert Opin. Drug Discovery"},{"key":"10.1016\/j.jns.2020.116903_bb0010","doi-asserted-by":"crossref","unstructured":"Tsai JJ, Wu T, Leung H, Desudchit T, Tiamkao S, Lim KS, Dash A. Perampanel, an AMPA receptor antagonist: From clinical research to practice in clinical settings. Acta Neurol. Scand. 137 (218) 378\u2013391. doi: https:\/\/doi.org\/10.1111\/ane.12879.","DOI":"10.1111\/ane.12879"},{"key":"10.1016\/j.jns.2020.116903_bb0015","doi-asserted-by":"crossref","first-page":"56","DOI":"10.5698\/1535-7511-11.2.56","article-title":"Revisiting AMPA receptors as an antiepileptic drug target","volume":"11","author":"Rogawski","year":"2011","journal-title":"Epilepsy Curr."},{"key":"10.1016\/j.jns.2020.116903_bb0020","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S0306-4522(99)00392-9","article-title":"Ionotropic glutamate and GABA receptors in human epileptic neocortical tissue: quantitative in vitro receptor autoradiography","volume":"94","author":"Zilles","year":"1999","journal-title":"Neuroscience."},{"key":"10.1016\/j.jns.2020.116903_bb0025","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.nbd.2003.11.006","article-title":"RNA editing (R\/G site) and flip-flop splicing of the AMPA receptor subunit GluR2 in nervous tissue of epilepsy patients","volume":"15","author":"Vollmar","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jns.2020.116903_bb0030","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.neuropharm.2015.03.014","article-title":"The AMPA receptor antagonist NBQX exerts anti-seizure but not antiepileptogenic effects in the intrahippocampal kainate mouse model of mesial temporal lobe epilepsy","volume":"95","author":"Twele","year":"2015","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.jns.2020.116903_bb0035","doi-asserted-by":"crossref","first-page":"P3.270","DOI":"10.1212\/WNL.82.10_supplement.P3.270","article-title":"Anti-seizure effects of Perampanel in combination with other antiepileptic drugs (AEDs) in a rat amygdala kindling model (P3.270)","volume":"82","author":"Wu","year":"2014","journal-title":"Neurology."},{"key":"10.1016\/j.jns.2020.116903_bb0040","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/j.1528-1167.2011.03109.x","article-title":"Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy","volume":"52","author":"Hanada","year":"2011","journal-title":"Epilepsia."},{"key":"10.1016\/j.jns.2020.116903_bb0045","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/epi.13629","article-title":"Perampanel effects in the WAG\/Rij rat model of epileptogenesis, absence epilepsy, and comorbid depressive-like behavior","volume":"58","author":"Citraro","year":"2017","journal-title":"Epilepsia."},{"key":"10.1016\/j.jns.2020.116903_bb0050","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.eplepsyres.2015.09.002","article-title":"Analysis of pooled phase III trials of adjunctive perampanel for epilepsy: impact of mechanism of action and pharmacokinetics on clinical outcomes","volume":"117","author":"Kwan","year":"2015","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.jns.2020.116903_bb0055","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.seizure.2018.09.012","article-title":"Long-term tolerability, safety and efficacy of adjunctive perampanel in the open-label, dose-ascending study 231 and extension study 233 in Japanese patients with epilepsy","volume":"62","author":"Usui","year":"2018","journal-title":"Seizure."},{"key":"10.1016\/j.jns.2020.116903_bb0060","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.eplepsyres.2015.04.011","article-title":"Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel","volume":"114","author":"Montouris","year":"2015","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.jns.2020.116903_bb0065","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1212\/WNL.0000000000001930","article-title":"Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy","volume":"85","author":"French","year":"2015","journal-title":"Neurology."},{"key":"10.1016\/j.jns.2020.116903_bb0070","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1111\/epi.14520","article-title":"Perampanel in routine clinical use across Europe: pooled, multicenter, observational data","volume":"59","author":"Rohracher","year":"2018","journal-title":"Epilepsia."},{"key":"10.1016\/j.jns.2020.116903_bb0075","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1111\/epi.14522","article-title":"Perampanel in routine clinical use in idiopathic generalized epilepsy: The 12-month GENERAL study","volume":"59","author":"Villanueva","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.jns.2020.116903_bb0080","first-page":"1","article-title":"Evaluation of perampanel as monotherapy for focal seizures: experience from open-label extension studies","volume":"9","author":"Kwan","year":"2019","journal-title":"Epilepsy Behav Case Rep."},{"key":"10.1016\/j.jns.2020.116903_bb0085","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.yebeh.2015.04.005","article-title":"Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit","volume":"49","author":"Rohracher","year":"2015","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.jns.2020.116903_bb0090","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.yebeh.2015.01.036","article-title":"Efficacy of perampanel in refractory nonconvulsive status epilepticus and simple partial status epilepticus","volume":"45","author":"Redecker","year":"2015","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.jns.2020.116903_bb0095","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ebcr.2017.09.004","article-title":"Efficacy of perampanel in a patient with epilepsia partialis continua","volume":"8","author":"Argente-Escrig","year":"2017","journal-title":"Epilepsy Behav Case Rep."},{"key":"10.1016\/j.jns.2020.116903_bb0100","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/WCO.0b013e3282f36ccd","article-title":"The natural history of mesial temporal lobe epilepsy","volume":"21","author":"Berg","year":"2008","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.jns.2020.116903_bb0105","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1517\/14656566.2015.1084504","article-title":"Perspectives on treatment options for mesial temporal lobe epilepsy with hippocampal sclerosis","volume":"16","author":"Palleria","year":"2015","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.jns.2020.116903_bb0110","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia."},{"key":"10.1016\/j.jns.2020.116903_bb0115","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia."},{"key":"10.1016\/j.jns.2020.116903_bb0120","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/epi.13670","article-title":"Operational classification of seizure types by the international league against epilepsy: position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Fisher","year":"2017","journal-title":"Epilepsia."},{"key":"10.1016\/j.jns.2020.116903_bb0125","first-page":"27","article-title":"Overview of using T1\/T2 and 10-10 subtemporal electrode chains for localizing EEG abnormalities","volume":"53","author":"Feravich","year":"2013","journal-title":"Neurodiagn J."},{"key":"10.1016\/j.jns.2020.116903_bb0130","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1212\/WNL.0000000000002674","article-title":"Long-term outcome of mild mesial temporal lobe epilepsy","volume":"86","author":"Labate","year":"2016","journal-title":"Neurology."},{"key":"10.1016\/j.jns.2020.116903_bb0135","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/epi.15612","article-title":"Recommendations for the use of structural magnetic resonance imaging in the care of patients with epilepsy: a consensus report from the international league against epilepsy neuroimaging task force","volume":"60","author":"Bernasconi","year":"2019","journal-title":"Epilepsia."},{"key":"10.1016\/j.jns.2020.116903_bb0140","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1528-1157.1989.tb05316.x","volume":"30","year":"1989","journal-title":"Epilepsia"},{"key":"10.1016\/j.jns.2020.116903_bb0145","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1212\/01.wnl.0000198208.59347.96","article-title":"MRI evidence of mesial temporal sclerosis in sporadic \u201cbenign\u201d temporal lobe epilepsy","volume":"66","author":"Labate","year":"2006","journal-title":"Neurology."},{"key":"10.1016\/j.jns.2020.116903_bb0150","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1528-1167.2009.02310.x","article-title":"Voxel-based morphometry of sporadic epileptic patients with mesiotemporal sclerosis","volume":"51","author":"Labate","year":"2010","journal-title":"Epilepsia."},{"key":"10.1016\/j.jns.2020.116903_bb0155","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40263-016-0406-8","article-title":"Tolerability and safety of commonly used antiepileptic drugs in adolescents and adults: a Clinician's overview","volume":"31","author":"Brodie","year":"2017","journal-title":"CNS Drugs."},{"key":"10.1016\/j.jns.2020.116903_bb0160","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jns.2018.04.017","article-title":"Perampanel as adjunctive therapy in highly refractory epilepsies: real-world data from an Italian tertiary care epilepsy Centre","volume":"39","author":"Morano","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2020.116903_bb0165","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/ane.12558","article-title":"Perampanel as add-on treatment in refractory focal epilepsy. The Dianalund experience","volume":"134","author":"Juhl","year":"2016","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.jns.2020.116903_bb0170","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1528-1167.2012.03638.x","article-title":"Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305","volume":"54","author":"French","year":"2013","journal-title":"Epilepsia."},{"key":"10.1016\/j.jns.2020.116903_bb0175","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.eplepsyres.2014.03.015","article-title":"A multicenter survey of clinical experiences with perampanel in real life in Germany and Austria","volume":"108","author":"Steinhoff","year":"2014","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.jns.2020.116903_bb0180","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/epi.12212","article-title":"Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies","volume":"54","author":"Steinhoff","year":"2013","journal-title":"Epilepsia."},{"key":"10.1016\/j.jns.2020.116903_bb0185","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eplepsyres.2016.08.021","article-title":"Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies-An Italian observational multicenter study","volume":"127","author":"De Liso","year":"2016","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.jns.2020.116903_bb0190","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.eplepsyres.2016.08.001","article-title":"Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA study","volume":"126","author":"Villanueva","year":"2016","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.jns.2020.116903_bb0195","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1080\/14656566.2017.1392509","article-title":"AMPA receptors and perampanel behind selected epilepsies: current evidence and future perspectives","volume":"18","author":"Di Bonaventura","year":"2017","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.jns.2020.116903_bb0200","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/epi.12220","article-title":"International consensus classification of hippocampal sclerosis in temporal lobe epilepsy: a task force report from the ILAE commission on diagnostic methods","volume":"54","author":"Bl\u00fcmcke","year":"2013","journal-title":"Epilepsia."},{"key":"10.1016\/j.jns.2020.116903_bb0205","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.seizure.2019.04.013","article-title":"Perampanel for the treatment of epilepsy; longitudinal actuarial analysis and dose responses based on monthly outcomes","volume":"69","author":"Stavropoulos","year":"2019","journal-title":"Seizure."},{"key":"10.1016\/j.jns.2020.116903_bb0210","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.seizure.2013.02.002","article-title":"Early predictors of outcome in newly diagnosed epilepsy","volume":"22","author":"Mohanraj","year":"2013","journal-title":"Seizure."},{"key":"10.1016\/j.jns.2020.116903_bb0215","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2020.116903_bb0220","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1212\/WNL.0000000000001558","article-title":"Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy","volume":"84","author":"Gidal","year":"2015","journal-title":"Neurology."},{"key":"10.1016\/j.jns.2020.116903_bb0225","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/ane.12529","article-title":"Perampanel for focal epilepsy: insights from early clinical experience","volume":"133","author":"Trinka","year":"2016","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.jns.2020.116903_bb0230","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/1756285616661115","article-title":"Two-year real-world experience with perampanel in patients with refractory focal epilepsy: Austrian data","volume":"9","author":"Rohracher","year":"2016","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.jns.2020.116903_bb0235","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1111\/epi.13054","article-title":"Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel","volume":"56","author":"Ettinger","year":"2015","journal-title":"Epilepsia."},{"key":"10.1016\/j.jns.2020.116903_bb0240","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2174\/157488906778773698","article-title":"AMPA receptor antagonists: potential therapeutic applications","volume":"1","author":"Mattes","year":"2006","journal-title":"Recent Pat CNS Drug Discov."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X20302409?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X20302409?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:50:56Z","timestamp":1758383456000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X20302409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":48,"alternative-id":["S0022510X20302409"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2020.116903","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy of perampanel as adjunctive therapy in drug-resistant focal epilepsy in a \u201creal world\u201d context: focus on temporal lobe epilepsy","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2020.116903","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116903"}}